Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Frontline Nivolumab/Ipilimumab Improves Response in mRCC

August 16th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved the objective response rate and duration of response compared with sunitinib (Sutent) in patients with treatment-naïve metastatic renal cell carcinoma, according to CheckMate-214.

Testing Picture Is Coming Into Sharper Focus for Familial and Hereditary Prostate Cancer

August 16th 2017

Research into the biology of prostate cancer has resulted in a growing understanding of the molecular drivers of the malignancy, resulting in a rapid evolution of genetic testing that is poised to revolutionize the diagnosis and care of at-risk men as well as those who have the disease.

Dr. Choyke Discusses Screening in Prostate Cancer

August 16th 2017

Peter Choyke, MD, FACR, chief of the Molecular Imaging Program, National Cancer Institute, discusses screening in prostate cancer.

Dr. Atkins Discusses Response to Atezolizumab in RCC

August 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.

The Metamorphosis of the Clinical Urologist

August 15th 2017

Raoul S. Concepcion, MD, FACS, shares his insight on the evolving role of the clinical urologist.

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

August 15th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

First-of-Its-Kind Multidisciplinary Guidelines for MIBC Treatment

August 14th 2017

A first-ever collaboration between the American Urological Association and other prominent urological groups has created a multidisciplinary set of guidelines on treating patients with nonmetastatic muscle-invasive bladder cancer (MIBC).

Dr. Gupta Discusses the Shifting Landscape of Kidney Cancer

August 11th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.

The Clinical Value of MRI Testing in Prostate Cancer

August 11th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses the clinical value of MRI testing in prostate cancer.

Dr. Hammers on the Future of Treatments for RCC

August 11th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

Early Chemo Linked to Improved PFS in High-Volume Metastatic Prostate Cancer

August 10th 2017

Patients with high-volume, castration-naïve metastatic prostate cancer may have superior progression-free survival outcomes when treated with early docetaxel.

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

August 10th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Dr. Kaouk on Challenges Facing Surgery for RCC

August 10th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses challenges regarding robotic surgery for patients with renal cell carcinoma (RCC).

Dr. Feldman on Managing Patients With Prostate Cancer Under Active Surveillance

August 9th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses managing patients with prostate cancer under active surveillance.

Dr. Lallas on Ongoing Trials Investigating Immunotherapy for GU Cancer

August 8th 2017

Costas Lallas, MD, professor at Sidney Kimmel Medical College, Thomas Jefferson University Hospital, discusses ongoing trials investigating immunotherapy regimens for patients with genitourinary malignancies.

Dr. Chowdhury on Sequencing of Immunotherapy Regimens for RCC

August 8th 2017

Simon Chowdhury, PhD, MA, MBBS, MRCP, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses sequencing of immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Black Discusses Immunotherapy Biomarkers in Bladder Cancer

August 8th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses immunotherapy biomarkers in bladder cancer.

Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

August 8th 2017

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

August 7th 2017

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

Genomic Landscape of Prostate Cancer Aligns With Breast Cancer Subtypes

August 4th 2017

A comparison of the genomic risk profiles of patients with low-risk prostate cancer who are candidates for active surveillance against higher-risk patients, discovered that substantial genomic heterogeneity exists among patients with prostate cancer.